Please login to the form below
telaprevir
This page shows the latest telaprevir news and features for those working in and with pharma, biotech and healthcare.
Leiden reassures on key role at Vertex
The company had been making losses for decades, but had won approval for its oral hepatitis C treatment Incivek (telaprevir) around this time, which became a blockbuster drug for the company.
Latest news
-
2015's 'premium' prices dissuaded J&J from acquisitions, says Gorsky
to $8.1bn despite heavy competition to hepatitis C therapies Olysio (simeprevir) and Incivo (telaprevir) from Gilead and AbbVie.
-
Access to new hep C treatments put under the spotlight
telaprevir). But NICE has not recommended the use of Daklinza-based regimens to treat patients with genotype 3 of the disease - which accounts for around 45% of all cases in England,
-
FDA approves four new medicines across multiple areas
and Vertex' Incivek (telaprevir).
-
J&J starts to feel biosimilar competition bite
toll on J&J's Olysio (simeprevir) and Incivek (telaprevir) products.
-
Top biotech firms saw sales jump in 2014
Dion added: “This drop was largely attributable to sliding sales of Incivek (telaprevir), Vertex's hepatitis C virus protease inhibitor, which fell by $442.3m compared with 2013, primarily as a
More from news
Approximately 0 fully matching, plus 35 partially matching documents found.
Latest Intelligence
-
Deal Watch table for November 2013
172. Vertex / Janssen. Royalty sale. Sale of product royalty rights relating to INCIVO (telaprevir) to Janssen Pharmaceutica.
-
Interview: Cesar Rodriguez, Janssen
Rodriguez also references infectious diseases as a stronghold for the company, mentioning the victory for hepatitis C treatment telaprevir in the 2012 UK Prix Galien Innovative Product Award.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- US secures 100 million doses of Sanofi/GSK’s COVID-19 vaccine
- New study identifies drugs that are safe to use in COVID-19 treatment
- How will the events and exhibitions industry change post-Coronavirus?
- China’s CanSino Biologics reveals phase 2 coronavirus vaccine results
- Roche’s Tecentriq combo scores FDA approval for melanoma
- AbbVie exits Voyager alliance for Alzheimer’s/Parkinson’s gene therapies
- Artificial Intelligence in Digital Therapeutics
- Virtual Reality in Medicine and Clinical Research
- J&J inks $1bn deal with US for coronavirus vaccine
- Novartis builds its case for novel MS treatment ofatumumab
- Pfizer’s Xalkori follow-up Lorbrena hits the mark in first-line lung cancer
- Award-winning agency Porterhouse Medical Group joins imc group with Waterland Private Equity’s support
PMHub
3 Monkeys Zeno
3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...
Latest intelligence
- Virtual Engagement At Porterhouse: Reflections on the past few months
- A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
- July 2020: diversity and inclusion in clinical trials round-up
- COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
- Medical Device Clinical Trials 2020
- In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...
Quick links
Infographics
